{"nctId":"NCT00595270","briefTitle":"Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","startDateStruct":{"date":"2005-10"},"conditions":["Japanese Encephalitis"],"count":349,"armGroups":[{"label":"IC51","type":"OTHER","interventionNames":["Biological: IC51"]}],"interventions":[{"name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Written informed consent obtained prior to study entry\n* Subjects correctly included in and having completed study IC51-304 according to the protocol.\n\nExclusion Criteria:\n\n* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period\n* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy\n* Pregnancy, lactation or unreliable contraception in female subjects","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination","description":"Seroprotection rate (SPR) (anti-JEV neutralizing antibody titer â‰¥ 1:10) 24 months (M24) after the primary vaccination - imputed; Persistence of immunogenicity (SPR) at M24 defined as:\n\n* pos. (positive) (persistent): Subjects\n\n  * with a non-missing, pos. seroconversion at D56 (Study IC51-304) and\n  * without booster at M11 or M23 and\n  * with non-missing, seroprotection (SP) pos. PRNT50 at M6 or M12 and\n  * with non-missing, SP pos. PRNT50 at M24\n* neg. (negative) (non-persistent): Subjects with\n\n  * missing or neg. seroconversion at D56 (Study IC51-304) or\n  * booster at M11 or at M23, or\n  * non-missing, SP neg. PRNT50 at M6 or M12 or\n  * missing PRNT50 at both M6 and M12 or\n  * missing or SP neg. PRNT50 (serum dilution giving 50% reduction in plaques in a Plaque Reduction Neutralization Test) at M24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"SPR 24 Months After the Primary Vaccination (Observed)","description":"Persistence of immunogenicity (SPR) at M24 (observed) defined as :\n\n* positive (persistent): Subjects\n\n  * with a non-missing, positive seroconversion at D56 (Study IC51-304), and\n  * who did not receive a booster dose at Visit 2 (M11) or Visit 4 (M23), and\n  * with a non-missing, SP positive PRNT50 result at Visit 1 (M6) or Visit 3 (M12), and\n  * with a non-missing, SP positive PRNT50 result at Visit 5 (M24)\n* negative (non-persistent): Subjects\n\n  * with missing or negative seroconversion at D56 (Study IC51-304), or\n  * who did receive a booster dose at Visit 2 (M11) or at Visit 4 (M23), or\n  * with a non-missing, SP negative PRNT50 result at Visit 1 (M6) or Visit 3 (M12), or\n  * with a missing PRNT50 result at both Visit 1 (M6) and Visit 3 (M12), or\n  * with a non-missing, SP negative PRNT50 result at Visit 5 (M24)","classes":[]},{"type":"SECONDARY","title":"Persistent and Actual SPR 6, 12 and 24 Months After Primary Vaccination","description":null,"classes":[]},{"type":"SECONDARY","title":"Persistent and Actual GMT 6, 12 and 24 Months After Primary Vaccination","description":null,"classes":[]},{"type":"SECONDARY","title":"SCR 1 Month After the Booster Doses","description":null,"classes":[]},{"type":"SECONDARY","title":"GMT 1month After Booster Doses","description":null,"classes":[]},{"type":"SECONDARY","title":"Safety Profile of IC51","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":116},"commonTop":["Nasopharyngitis","Headache","Fatique","Influenza Like Ilness","Pharyngolaryngeal Pain"]}}}